耳鼻咽喉科指南

订阅

MedSci主页 / 所有栏目 / 耳鼻咽喉科指南

鼻用糖皮质激素治疗变应性鼻炎专家共识(2021,上海)

2021-08-30 中国耳鼻咽喉科相关专家组（统称） 中国耳鼻咽喉颅底外科杂志. 2021,27(04)

变应性鼻炎

本文系中国鼻病研究协作组召集国内青年鼻科专家,基于临床经验和循证医学证据制订的鼻用糖皮质激素治疗变应性鼻炎的专家共识。本共识从鼻用糖皮质激素的作用原理、药理特点和临床应用等方面系统总结了鼻用糖皮质激素

中文标题：

鼻用糖皮质激素治疗变应性鼻炎专家共识(2021,上海)

发布机构：

中国耳鼻咽喉科相关专家组（统称）

发布日期：

2021-08-30

简要介绍：

本文系中国鼻病研究协作组召集国内青年鼻科专家,基于临床经验和循证医学证据制订的鼻用糖皮质激素治疗变应性鼻炎的专家共识。本共识从鼻用糖皮质激素的作用原理、药理特点和临床应用等方面系统总结了鼻用糖皮质激素在治疗变应性鼻炎中的作用、临床应用要旨和注意事项,旨在进一步规范变应性鼻炎的诊疗,指导医师进行合理的用药,以提高变应性鼻炎的治疗疗效和患者的就医满意度。 
 

相关资料下载：
[AttachmentFileName(sort=1, fileName=鼻用糖皮质激素治疗变应性鼻炎专家共识_2021_上海_杨钦泰.pdf)] GetToolGuiderByIdResponse(projectId=1, id=28e021c002185025, title=鼻用糖皮质激素治疗变应性鼻炎专家共识(2021,上海), enTitle=, guiderFrom=中国耳鼻咽喉颅底外科杂志. 2021,27(04), authorId=0, author=, summary=本文系中国鼻病研究协作组召集国内青年鼻科专家,基于临床经验和循证医学证据制订的鼻用糖皮质激素治疗变应性鼻炎的专家共识。本共识从鼻用糖皮质激素的作用原理、药理特点和临床应用等方面系统总结了鼻用糖皮质激素, cover=https://img.medsci.cn/2021914/1631561755895_2020535.jpg, journalId=0, articlesId=null, associationId=895, associationName=中国耳鼻咽喉科相关专家组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Mon Aug 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="row"><span id="ChDivSummary" class="abstract-text" style="color: #666666;">本文系中国鼻病研究协作组召集国内青年鼻科专家,基于临床经验和循证医学证据制订的鼻用糖皮质激素治疗变应性鼻炎的专家共识。本共识从鼻用糖皮质激素的作用原理、药理特点和临床应用等方面系统总结了鼻用糖皮质激素在治疗变应性鼻炎中的作用、临床应用要旨和注意事项,旨在进一步规范变应性鼻炎的诊疗,指导医师进行合理的用药,以提高变应性鼻炎的治疗疗效和患者的就医满意度。&nbsp;</span></div> <div class="row">&nbsp;</div>, tagList=[TagDto(tagId=27739, tagName=变应性鼻炎)], categoryList=[CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=27739, guiderKeyword=变应性鼻炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4947, appHits=261, showAppHits=0, pcHits=750, showPcHits=4652, likes=1, shares=32, comments=11, approvalStatus=1, publishedTime=Tue Sep 14 03:58:39 CST 2021, publishedTimeString=2021-08-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Sep 14 03:36:08 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 12:33:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=鼻用糖皮质激素治疗变应性鼻炎专家共识_2021_上海_杨钦泰.pdf)])
鼻用糖皮质激素治疗变应性鼻炎专家共识_2021_上海_杨钦泰.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2119075, encodeId=236821190e525, content=很详细和有帮助，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 12 15:14:51 CST 2023, time=2023-03-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1193406, encodeId=34991193406db, content=学些, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0aad6503345, createdName=ms5000001450015176, createdTime=Mon Feb 14 21:10:30 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188836, encodeId=2638118883620, content=马克, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d61636229, createdName=1dd94fafm20(暂无匿称), createdTime=Fri Jan 28 15:54:38 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188784, encodeId=60f01188e845d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2726160232, createdName=ms4000000144862963, createdTime=Fri Jan 28 11:14:01 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182605, encodeId=9179118260512, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29666444156, createdName=ms8000001953743897, createdTime=Sun Jan 09 19:50:38 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2023-03-12 ms8000000684966679 来自上海

    很详细和有帮助，学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2119075, encodeId=236821190e525, content=很详细和有帮助，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 12 15:14:51 CST 2023, time=2023-03-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1193406, encodeId=34991193406db, content=学些, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0aad6503345, createdName=ms5000001450015176, createdTime=Mon Feb 14 21:10:30 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188836, encodeId=2638118883620, content=马克, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d61636229, createdName=1dd94fafm20(暂无匿称), createdTime=Fri Jan 28 15:54:38 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188784, encodeId=60f01188e845d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2726160232, createdName=ms4000000144862963, createdTime=Fri Jan 28 11:14:01 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182605, encodeId=9179118260512, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29666444156, createdName=ms8000001953743897, createdTime=Sun Jan 09 19:50:38 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-02-14 ms5000001450015176

    学些

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2119075, encodeId=236821190e525, content=很详细和有帮助，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 12 15:14:51 CST 2023, time=2023-03-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1193406, encodeId=34991193406db, content=学些, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0aad6503345, createdName=ms5000001450015176, createdTime=Mon Feb 14 21:10:30 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188836, encodeId=2638118883620, content=马克, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d61636229, createdName=1dd94fafm20(暂无匿称), createdTime=Fri Jan 28 15:54:38 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188784, encodeId=60f01188e845d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2726160232, createdName=ms4000000144862963, createdTime=Fri Jan 28 11:14:01 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182605, encodeId=9179118260512, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29666444156, createdName=ms8000001953743897, createdTime=Sun Jan 09 19:50:38 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-28 1dd94fafm20(暂无匿称)

    马克

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2119075, encodeId=236821190e525, content=很详细和有帮助，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 12 15:14:51 CST 2023, time=2023-03-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1193406, encodeId=34991193406db, content=学些, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0aad6503345, createdName=ms5000001450015176, createdTime=Mon Feb 14 21:10:30 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188836, encodeId=2638118883620, content=马克, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d61636229, createdName=1dd94fafm20(暂无匿称), createdTime=Fri Jan 28 15:54:38 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188784, encodeId=60f01188e845d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2726160232, createdName=ms4000000144862963, createdTime=Fri Jan 28 11:14:01 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182605, encodeId=9179118260512, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29666444156, createdName=ms8000001953743897, createdTime=Sun Jan 09 19:50:38 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-28 ms4000000144862963

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2119075, encodeId=236821190e525, content=很详细和有帮助，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 12 15:14:51 CST 2023, time=2023-03-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1193406, encodeId=34991193406db, content=学些, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0aad6503345, createdName=ms5000001450015176, createdTime=Mon Feb 14 21:10:30 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188836, encodeId=2638118883620, content=马克, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d61636229, createdName=1dd94fafm20(暂无匿称), createdTime=Fri Jan 28 15:54:38 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188784, encodeId=60f01188e845d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2726160232, createdName=ms4000000144862963, createdTime=Fri Jan 28 11:14:01 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182605, encodeId=9179118260512, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29666444156, createdName=ms8000001953743897, createdTime=Sun Jan 09 19:50:38 CST 2022, time=2022-01-09, status=1, ipAttribution=)]
    2022-01-09 ms8000001953743897

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2021 土耳其指南：变应性鼻炎的诊断和治疗

国外耳鼻喉相关专家组（统称） · 2021-05-25

变应性鼻炎及过敏性哮喘舌下免疫治疗中国指南

中华医学会变态反应学分会 · 2021-04-02

口服H1抗组胺药治疗变应性鼻炎2018广州共识

中国耳鼻咽喉科相关专家组（统称） · 2018-06-04

儿童普通感冒与变应性鼻炎早期识别和诊治专家共识

中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会 · 2017-02-20

【指南专题】变应性鼻炎如何诊断与治疗？答案在这里！

暂未更新 · 2017-03-13

变应性鼻炎诊断和治疗指南（2015年，天津）

中华医学会耳鼻咽喉头颈外科学分会 · 2016-01-04

拓展阅读

变应性鼻炎诊断和治疗指南（2015年，天津）

中华医学会耳鼻咽喉头颈外科学分会 · 2016-01-04

【指南专题】变应性鼻炎如何诊断与治疗？答案在这里！

暂未更新 · 2017-03-13

儿童普通感冒与变应性鼻炎早期识别和诊治专家共识

中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会 · 2017-02-20

口服H1抗组胺药治疗变应性鼻炎2018广州共识

中国耳鼻咽喉科相关专家组（统称） · 2018-06-04

变应性鼻炎及过敏性哮喘舌下免疫治疗中国指南

中华医学会变态反应学分会 · 2021-04-02

2021 土耳其指南：变应性鼻炎的诊断和治疗

国外耳鼻喉相关专家组（统称） · 2021-05-25